New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
18:58 EDTTHO, YUM, BIDU, HOLX, SIMO, IDIX, OGXI, CLDXOn The Fly: After Hours Movers
UP AFTER PRELIMINARY EARNINGS: Thor Industries (THO), up 3.7% after preliminary Q2 revenue beats estimates... DOWN AFTER EARNINGS: Yum! Brands (YUM), down 5.4% after cutting its FY13 EPS view, reporting Q4 China SSS down 6%... Baidu (BIDU), down 5.2%... Hologic (HOLX), down 4.1%... Silicon Motion (SIMO), down 10.9% after reporting Q4 earnings and saying it sees Q1 revenue own 15%-25% sequentially... ALSO LOWER: Idenix (IDIX), down 5.9% after announcing it had discontinued clinical development for a hepatitis C treatment... OncoGenex (OGXI), down 3.3% after disclosing the resignation of its CFO... Celldex (CLDX), down 3.3% after filing to sell $75M in common stock.
News For THO;YUM;BIDU;HOLX;SIMO;IDIX;OGXI;CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
08:44 EDTBIDUBaidu upgraded to Buy at UBS
As reported previously, UBS upgraded Baidu to Buy from Neutral, citing expectations of better top-line growth and an optimistic outlook on mobile monetization. UBS raised its price target on Baidu to $272 from $212.
06:39 EDTBIDUBaidu upgraded to Buy from Neutral at UBS
Subscribe for More Information
September 26, 2014
11:02 EDTTHOThor Industries upgraded to Buy from Gradually Accumulate at Wellington Shields
Subscribe for More Information
10:01 EDTCLDXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:35 EDTCLDXCelldex initiated with an Outperform at Cowen
Subscribe for More Information
September 25, 2014
16:19 EDTTHOThor Industries to discontinue preliminary sales release beginning Q1
Thor announced that beginning with Q1, the company will discontinue its preliminary sales release. The company believes that ceasing the preliminary release will benefit investors by providing more detailed and comprehensive information regarding Thor's financial performance in a single release in coordination with the company's quarterly and annual filings with the SEC. The earnings release for Q1 is tentatively scheduled for December 1.
16:18 EDTTHOThor Industries reports Q4 EPS $1.25, consensus $1.23
Subscribe for More Information
15:29 EDTTHONotable companies reporting after market close
Subscribe for More Information
08:07 EDTCLDXCelldex initiates CDX-301 pilot study
Celldex Therapeutics announced the initiation of a pilot study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell transplantation, or HSCT. The study will explore the utility of CDX-301, also known as FMS-like tyrosine kinase-3 ligand or Flt3L, alone and in combination with Mozobil and is supported by preclinical data demonstrating that the combination of CDX-301 and Mozobil increased hematopoietic stem cell mobilization and improved transplantation of mobilized cells. The open-label, pilot study will enroll up to 36 participants, or 18 recipient/donor pairs, ages 18 to 65 across two sequentially enrolled cohorts in approximately 10 clinical trial sites in the United States. Study participants include patients with specified hematologic malignancies and Human Leukocyte Antigen, or HLA, sibling-matched healthy volunteers. The primary objective is to assess the safety and tolerability of CDX-301 when given with or without Mozobil. Secondary endpoints will evaluate the adequacy of the resultant grafts as determined by CD34+ yield, the cellular composition of the resultant grafts, and the safety and effectiveness of the resulting grafts across multiple measures.
September 23, 2014
09:37 EDTBIDUActive equity options trading on open
Subscribe for More Information
08:53 EDTTHOThor Industries outlook has improved, says BMO Capital
Subscribe for More Information
September 22, 2014
10:15 EDTHOLXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:04 EDTBIDUAltera and Baidu collaborate on FPGA-based acceleration for cloud data centers
Subscribe for More Information
05:32 EDTHOLXHologic upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
September 19, 2014
16:00 EDTBIDUOptions Update; September 19, 2014
Subscribe for More Information
09:37 EDTBIDUActive equity options trading on open
Subscribe for More Information
September 18, 2014
16:00 EDTBIDUOptions Update; September 18, 2014
Subscribe for More Information
13:47 EDTYUMPizza Hut opens first restaurant in Africa, plans to open dozens more
Subscribe for More Information
07:52 EDTYUMPizza Hut testing 30% lower calorie pie, USA Today reports
Subscribe for More Information
07:35 EDTBIDUBaidu volatility low into Alibaba IPO
Baidu September call option implied volatility is at 28, September weekly is at 28, October is at 32, December is at 33; compared to its 26-week average of 38 according to Track Data, suggesting decreasing price movement.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use